Pretracheal Lymph Node Subdivision in Predicting Contralateral Central Lymph Node Metastasis for Unilateral Papillary Thyroid Carcinoma: Preliminary Results

Qiang Chen†, Yang Liu†, Wei Lu, Lingyun Zhang, Anping Su, Feng Liu and Jingqiang Zhu*

Department of Thyroid and Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu, China

Background: The aims of this study were to assess the clinical value of pretracheal lymph node subdivision in identifying patients with contralateral central lymph node metastasis (CLNM) and risk factors for occult contralateral CLNM in unilateral PTC.

Methods: A total of 139 unilateral PTC patients with a clinically node-negative neck (cN0) who underwent bilateral central neck dissection (CND) were prospectively enrolled. Intraoperatively, the pretracheal region was further divided into ipsilateral and contralateral subregions. Ipsilateral and contralateral pretracheal lymph nodes (LNs) as well as other CLNs (prelaryngeal, ipsilateral paratracheal and contralateral paratracheal) were labeled separately and sent for pathological examination. Demographic and clinicopathologic variables were analyzed to identify factors predictive of contralateral CLNM.

Results: Of 139 patients, bilateral CLNM was present in 37 (26.6%) patients. Contralateral pretracheal LNM was significantly associated with contralateral CLNM. In multivariate analysis, prelaryngeal LNM ($P = 0.004$, odds ratio = 3.457) and contralateral pretracheal LNM ($P = 0.006$, odds ratio = 3.362) were identified as risk factors for contralateral CLNM. Neither neck recurrence nor distant metastasis was observed within the mean follow-up duration of 9.1 ± 1.8 months.

Conclusions: In most unilateral cN0 PTCs, performing ipsilateral CND is appropriate, while patients presenting with evident nodal disease intraoperatively or preoperatively in the contralateral central neck should undergo bilateral CND. Intraoperative re-evaluation of prelaryngeal and contralateral pretracheal LNs may be helpful in determining the extent of CND.

Keywords: pretracheal lymph node, central neck dissection, papillary thyroid carcinoma, central lymph node metastasis, clinically node-negative neck
INTRODUCTION

Despite the excellent overall prognosis, papillary thyroid carcinoma (PTC) is characterized by early regional lymph node metastasis (LN), and the central neck compartment (level VI) is usually the first involved region. Central lymph node metastasis (CLNM) has been reported in 30%–90% of patients who undergo elective central neck dissection (CND) (1, 2). Ipsilateral CND is considered necessary for patients with suspicious nodal metastasis, but when to perform contralateral CND in unilateral PTC is controversial. Bilateral CND has been recommended by some endocrine surgeons because it can enable complete nodal dissection, which may reduce the risk of locoregional recurrence and distant metastasis (3–5). In fact, however, most patients with unilateral PTC only have ipsilateral CLNM without contralateral CLNM. On the other hand, bilateral CND is associated with a higher rate of surgical complications such as hypoparathyroidism and recurrent laryngeal nerve injury, even if it is performed in experienced hands (6, 7). Nonetheless, the risk of nodal metastasis and locoregional recurrence in the contralateral central neck cannot be neglected (8). It is important to understand the characteristics and prognosis of CLNM in unilateral PTC. Therefore, accurate assessment of patients at high risk of CLNM, especially contralateral CLNM, may facilitate determining the appropriate extent of CND, which could decrease unnecessary morbidities caused by bilateral CND.

Pretracheal lymph nodes (LNs) have been found to be closely connected with ipsilateral/contralateral central lymph nodes (CLNs) (9). Although some studies have investigated the risk factors for contralateral CLNM, there have been few studies evaluating whether pretracheal LNs could be used as sentinel LNs that aid in identifying patients with occult contralateral CLNM. In this study, we hypothesized that pretracheal LN subdivision could be of value for the identification of PTC patients with occult contralateral CLNM.

The aims of the present study were to evaluate the clinical value of pretracheal LN subdivision to aid in surgical decision-making regarding the extent of CND and risk factors for occult contralateral CLNM in unilateral PTC.

MATERIALS AND METHODS

Patient Population

From October 2019 to December 2020, 193 patients consented to undergo pretracheal LN subdivision, total thyroidectomy and bilateral CND for the treatment of PTC in our institution. All patients had a preoperative diagnosis of PTC, and no suspicious neck LNs were detected by palpation or ultrasound (US) perioperatively (cN0). Patients with the following were excluded from this study: history of previous thyroidectomy, non-PTC carcinoma, PTC variants, isthmus tumor, bilateral tumors, and lateral neck dissection. Finally, 139 patients were prospectively enrolled in this study. This study was approved by the Institutional Review Board of West China Hospital, Sichuan University (IRB-HX2019012), and all patients provided written informed consent.

Surgical Procedures

A standardized surgical procedure was carried out in the present study to minimize morbidities and ensure comprehensive removal of LNs in the central compartment. CND was defined as a level VI dissection extending superiorly to the hyoid bone, inferiorly to the suprasternal notch, laterally to the carotid sheaths, and dorsally to the prevertebral fascia. Bilateral CND included the removal of prelaryngeal, pretracheal, and both the paratracheal nodes on the side of the tumor and contralateral to the tumor (10). Moreover, pretracheal LNs are further divided into ipsilateral pretracheal LNs and contralateral pretracheal LNs intraoperatively based on the middle line of the anterior wall of the trachea (Figure 1).

Histopathological Examination of Surgical Specimens

LNs in each subsite of the central compartment were separated and labeled after dissection and sent for pathological examination along with the resection thyroid specimens. Thyroid specimens and dissected LNs were microscopically examined by two or more experienced pathologists. The following factors were assessed: primary tumor size, multifocality, capsular invasion, extrathyroidal extension (ETE), chronic lymphocytic thyroiditis, the number of metastatic LNs, and the total number of LNs in each subsite. The pathological stage of thyroid cancer was determined in accordance with the 8th edition of the American Joint Committee on Cancer Staging Manual (11).

Postoperative Management and Follow-Up

Postoperative serum calcium and intact parathyroid hormone concentrations were measured in all patients. Patients who developed hypocalcemia were treated with oral calcium and vitamin D supplements, and those who developed significant symptoms were administered intravenous calcium gluconate. Transient hypocalcemia was defined as an ionized serum calcium concentration of <2.1 mmol/L and the calcium level recovered to normal within 6 months, while permanent hypocalcemia was defined as an ionized serum calcium concentration that remained below normal at ≥6 months after surgery and required oral calcium and vitamin D supplementation. Preoperative fibrolaryngoscopy examination was performed for each patient, while postoperative examination was selectively performed in the case who developed hoarseness after surgery. Vocal cord palsy that lasted for 6 months postoperatively was regarded as permanent. All patients received thyroid-stimulating hormone suppression therapy after surgery and underwent regular follow-up at 6-to 12-month intervals with clinical evaluation including serum thyroglobulin (Tg) level, ultrasonography (US) and CT. Locoregional recurrence was defined as the presence of tumors or metastatic LNs on cytological diagnosis. Radioactive iodine (RAI) therapy was performed based on tumor stage and risk factors, in accordance with the American Thyroid Association guidelines (10).

Statistical Analysis

Statistical analyses were performed using SPSS software (version 19.0, IBM Corp, Armonk, NY, USA), and a P value <0.05 was
considered to be statistically significant. Continuous variables are presented as the mean ± standard deviation (SD), and categorical variables are presented as numbers with percentages (%). Student’s t-test was used for continuous variables, and the chi-square test was used for categorical variables in univariate analysis. Multivariate analysis was performed by binary logistic regression to determine if the clinicopathological characteristics were risk factors for contralateral CLNM.

RESULTS

Clinicopathological Characteristics of 139 PTC Patients Who Underwent Total Thyroidectomy With Bilateral CND

The demographics and clinical data of the 139 patients (34 men and 105 women) are summarized in Table 1. The median age was 39 years (range, 18–72 years). Of these 139 patients, 89.9% (125/139) were <55 years old, and 10.1% (14/139) were ≥55 years old. The mean ± SD size of the primary tumor was 1.3 ± 0.7 cm (range, 0.6–3.7 cm). Fifty-six (40.3%) patients had a primary tumor ≤1 cm, and 83 (63.3%) patients had a primary tumor >1 cm. Multifocality was observed in 33 (23.7%) patients, capsular invasion was found in 66 (47.5%) patients, and ETE was confirmed in 31 (22.3%) patients. The mean ± SD number of dissected nodes was 5.4 ± 3.2 in the ipsilateral paratracheal region, 3.8 ± 3.0 in the contralateral paratracheal region, 1.4 ± 1.2 in the prelaryngeal region, and 3.8 ± 2.2 in the pretracheal region. One hundred and three (73.4%) patients had pretracheal LNM, 47 (33.8%) patients had prelaryngeal LNM, 88 (63.3%) patients had ipsilateral CLNM, and 37 (26.6%) patients had bilateral CLNM. Among these patients, 7 (5.0%) patients had isolated contralateral CLNM.

Risk Factors for Contralateral CLN Metastasis in 139 PTC Patients

In univariate analysis, prelaryngeal LNM (P = 0.002) and ipsilateral paratracheal LNM (P = 0.009) were significantly associated with contralateral CLNM (Table 2). Moreover, contralateral pretracheal LNM (P = 0.001) was significantly associated with contralateral CLNM, while pretracheal LNM was not associated with contralateral CLNM. Among patients with central lymph node metastasis, contralateral pretracheal lymph node positivity was significantly associated with patient age (P = 0.034) (Table 3). In multivariate analysis, prelaryngeal LNM (P = 0.004, odds ratio = 3.457) and contralateral pretracheal LNM (P = 0.006, odds ratio = 3.362) were independent predictive factors for contralateral CLNM (Table 4).

Postoperative Morbidities and RAI Therapy

Forty-five (32.4%) of 139 patients developed postoperative hypocalcemia and they all recovered within 6 months. Five patients developed hoarseness and were confirmed to have vocal cord palsy by fibrolaryngoscopic examination. Four of the 5 patients recovered to normal cord mobility within 6 months. Forty-nine (35.3%) patients received RAI therapy (100–150 mCi) after surgery, and no patient had neck recurrence (central or lateral) or distant metastasis during the mean follow-up duration of 9.1 ± 1.8 months (range, 6–20 months).

DISCUSSION

In most patients with PTC, cervical nodal metastasis generally occurs in a stepwise sequential fashion (12). Tumors located in the upper part of the thyroid and the pyramidal lobe usually first
# TABLE 1 | Clinicopathologic characteristics of patients.

| Variables                                      | Total number of patients | Age, median, yrs | <55 y/≥55 y, n (%) | Gender, n (%) | Primary tumor size, cm | ≤1 cm/>1 cm, n (%) | Multifocality, n (%) | Chronic lymphocytic thyroiditis, n (%) | Capsular invasion, n (%) | Extrathyroidal extension, n (%) | Pretracheal LNM, n (%) | Ipsilateral pretracheal LNM, n (%) | Ipsilateral CLNM, n (%) | Contralateral CLNM, n (%) |
|------------------------------------------------|--------------------------|------------------|--------------------|---------------|------------------------|---------------------|----------------------|-----------------------------------|-------------------------|--------------------------|-------------------------|-------------------------------|----------------------|--------------------------|
| Total number of patients                       | 139                      | 39 (18–72)       | 125 (89.9)/14 (10.1) |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Age, median, yrs                               | 39 (18–72)               |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| <55 y/≥55 y, n (%)                             | 125 (89.9)/14 (10.1)     |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Gender, n (%)                                  |                           |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Female                                         | 105 (75.5)               |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Male                                           | 34 (24.5)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Primary tumor size, cm                         | 1.3±0.7 (0.6–3.7)        |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| ≤1 cm/>1 cm, n (%)                             | 56 (40.3)/83 (59.7)      |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Multifocality, n (%)                           | 33 (23.7)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Chronic lymphocytic thyroiditis, n (%)         | 43 (30.9)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Capsular invasion, n (%)                       | 66 (47.5)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Extrathyroidal extension, n (%)                | 31 (22.3)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Pretracheal LNM, n (%)                         | 102 (73.4)               |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Ipsilateral pretracheal LNM, n (%)             | 73 (52.5)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Ipsilateral CLNM, n (%)                        | 68 (43.3)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |
| Contralateral CLNM, n (%)                      | 37 (26.6)                |                  |                    |               |                        |                     |                     |                                   |                         |                          |                         |                               |                      |                          |

CLNM, central lymph node metastasis; LNM, lymph node metastasis.

# TABLE 2 | Univariate analysis of clinicopathologic characteristics for contralateral CLNM.

| Contralateral CLNM, n (%) | P       |
|---------------------------|---------|
| Age, yrs                  | 1.000*  |
| <55                      | 33 (26.4) |
| ≥55                      | 4 (28.6)  |
| Gender                   | 0.118 |
| Female                   | 25 (23.8) |
| Male                     | 12 (35.3) |
| Primary tumor size, cm   | 0.126 |
| ≤1                       | 11 (19.6) |
| >1                       | 26 (31.3) |
| Capsular invasion        | 0.291 |
| Yes                      | 22 (33.3) |
| No                       | 10 (23.8) |
| Extrathyroidal extension | 0.422 |
| Yes                      | 5 (16.1)  |
| No                       | 10 (23.8) |
| Multifocality            | 0.922 |
| Yes                      | 9 (27.3)  |
| No                       | 28 (26.4) |
| Chronic lymphocytic thyroiditis | 0.289 |
| Yes                      | 14 (32.6) |
| No                       | 23 (24.0) |
| Pretracheal LNM          | 0.002 |
| Yes                      | 20 (42.6) |
| No                       | 17 (18.5) |
| Ipsilateral CLNM         | 0.009 |
| Yes                      | 30 (29.4) |
| No                       | 7 (18.9)  |
| Ipsilateral pretracheal LNM | 0.17   |
| Yes                      | 30 (34.1) |
| No                       | 7 (13.7)  |
| Contralateral pretracheal LNM | 0.001 |
| Yes                      | 23 (31.5) |
| No                       | 14 (21.2) |

CLNM, central lymph node metastasis; LNM, lymph node metastasis. *Fisher’s exact test.
metastasize to prelaryngeal and carotid triangular LNs, and those located in the middle and lower parts of the thyroid generally first metastasize to ipsilateral CLNs or pretracheal LNs. To the best of our knowledge, the majority of published studies reported that the region ipsilateral to the tumor is the most common metastatic region (2, 13, 14). In contrast, the results of this study showed that the subsite with the highest rate of LNM in the central neck was the pretracheal region (73.4%), followed by the ipsilateral paratracheal region (63.3%).

A few studies have described the pros and cons of prophylactic CND. Some endocrine surgeons recommended performing bilateral CND as comprehensive dissection of CLNs may reduce the risk of locoregional recurrence and facilitate achieving low Tg levels (1, 15–17). In contrast, others performed unilateral CND because most patients with unilateral PTC have a lower rate of contralateral CLNM. They argued that bilateral CND did not significantly improve survival but may increase the risk of postoperative morbidities (18, 19). The incidence of LNM to the contralateral paratracheal region in cN0 PTC patients has been reported to range from 9.8% to 30.6% (20–23). In the present study, we found that the rate of contralateral CLNM was 26.6% (37/139). Our findings also demonstrated that the incidence of contralateral CLNM was relatively low in unilateral cN0 PTC patients. Thus, the surgical extent of ipsilateral CND is sufficient for most unilateral PTCs.

However, ipsilateral CND means that there is a potential risk of locoregional recurrence in the contralateral paratracheal region. An accurate assessment of cervical lymph node status is the key to reducing the risk of locoregional recurrence and surgical complications. Preoperative US is helpful in detecting metastatic LNs in the neck, but the sensitivity is relatively low because of the overlying thyroid gland and trachea (24). In fact, a large proportion of PTC patients with node negative on preoperative US or palpation were found to have cervical LNM on pathological examination after surgery (24, 25). A few studies have suggested some risk factors for predicting contralateral CLNM in cN0 PTC. A multicenter study reported that contralateral CLNM was associated with ipsilateral paratracheal LNM (20). In another study, pretracheal and prelaryngeal LNM independently predicted contralateral CLNM (26). The results of this study also showed that patients with prelaryngeal LN involvement had a significantly higher rate of contralateral CLNM, and prelaryngeal LNM was an independent risk factor for contralateral CLNM. Recently, some endocrine surgeons have further investigated the value of intraoperative re-evaluation of prelaryngeal and pretracheal LNs through frozen section examination (FSE) in the decision-making of bilateral CND and found that FSE is a safe and effective strategy to decrease the need for a second-step CND (27, 28).

Theoretically, the risk of contralateral CLNM will increase when pretracheal LNs are positive. However, in our study, pretracheal LN metastasis was not associated with contralateral CLNM. In contrast, contralateral pretracheal LNM was significantly associated with contralateral CLNM, and contralateral pretracheal LNM was an independent predictor for contralateral CLNM. Our data suggest that pretracheal LN subdivision has potential value for clinical application, which is helpful for surgeons to determine the extent of CND. To the best of our knowledge, this was the first study assessing...
contralateral pretracheal LNM in predicting contralateral CLNM in unilateral cN0 PTC. Based on the results of our study, contralateral pretracheal LNs could be considered sentinel compartments in bilateral CND, and intraoperative FSE should be considered and performed. Locoregional recurrence after CND remains a critical issue in PTC, although the prognostic relevance of microscopic CLNM to recurrence is likely minimal in most cases. Unfortunately, we were unable to determine whether prophylactic contralateral CND is essential in patients with microscopic CLNM since there was a lack of comparison of the cohort group and a short follow-up period in this study. Therefore, we suggest that PTC patients with unilateral tumors presenting with evident nodal disease intraoperatively or preoperatively in the contralateral central neck should undergo therapeutic bilateral CND. Otherwise, ipsilateral CND may be appropriate.

It is evident that there are several limitations in this study. First, although it is conducted prospectively, a small sample size without comparative analysis cannot be overlooked. Further prospective, randomized trials with large sample size are warranted to validate the value of this intraoperative decision-making approach. Second, a longer follow-up duration is required to assess locoregional recurrence and survival. In spite of these limitations, our study has the merit of including cN0 PTC patients operated on with the same therapeutic protocol in the same institution.

**CONCLUSIONS**

Patients with unilateral PTC are at a relatively low risk of contralateral CLNM and CND limited to the ipsilateral side is appropriate. The results of the present study suggest that prelaryngeal LNM or contralateral pretracheal LNM increases the likelihood of contralateral CLNM. Therefore, intraoperative assessment of prelaryngeal and contralateral pretracheal LNs by using FSE is able to decide whether to perform contralateral CND in patients with unilateral PTC.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Institutional Review Board of West China Hospital, Sichuan University. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

JZ, designed and conceptualized the study. AS, FL and JZ, conducted the study. WL and LZ, collected the data. QC and YL, data analysis and manuscript writing. JZ and AS, interpreted data and refined the manuscript. All authors contributed to the study and approved the submitted version.

**REFERENCES**

1. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho J, et al. Nodal Yield, Morbidity, and Recurrence After Central Neck Dissection for Papillary Thyroid Carcinoma. *Surgery* (2005) 138(6):1095–100, discussion 1100-1. doi: 10.1016/j.surg.2005.09.013
2. Ji YB, Yoo HS, Song CM, Park CW, Lee CB, Tae K. Predictive Factors and Pattern of Central Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma. *Auris Nasus Larynx* (2016) 43(1):79–83. doi: 10.1016/j.anl.2015.09.005
3. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A Multicenter Cohort Study of Total Thyroidectomy and Routine Central Lymph Node Dissection for cN0 Papillary Thyroid Cancer. *Surgery* (2011) 150(6):1048–57. doi: 10.1016/j.surg.2011.09.003.
4. Raffaelli M, De Crea C, Sessa L, Tempere SE, Fadda G, Pontecorvi A, et al. Modulating the Extension of Thyroidectomy in Patients With Papillary Thyroid Carcinoma Pre-Operatively Eligible for Lobeectomy: Reliability of Ipsilateral Central Neck Dissection. *Endocrine* (2021) 72(2):437–44. doi: 10.1007/s00268-021-0829-3
5. Hartl DM, Mamelle E, Borget I, Leboulleux S, Mirghani H, Schlumberger M. Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma. *World J Surg* (2013) 37(8):1951–8. doi: 10.1007/s00268-013-2089-3.
6. Yoo HS, Shin MG, Ji YB, Song CM, Lee SH, Tae K. Optimal Extent of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma: Comparison of Unilateral Versus Bilateral Central Neck Dissection. *Asian J Surg* (2018) 41(4):363–9. doi: 10.1016/j.asjsur.2017.03.002
7. Raffaelli M, De Crea C, Sessa L, Giustacchini P, Revelli L, Bellantone C, et al. Prospective Evaluation of Total Thyroidectomy Versus Ipsilateral Versus Bilateral Central Neck Dissection in Patients With Clinically Node-Negative Papillary Thyroid Carcinoma. *Surgery* (2012) 152(6):957–64. doi: 10.1016/j.surg.2012.08.053
8. Giordano D, Botti C, Piana S, Castellucci A, Frasoldati A, Zini M, et al. Hemithyroidectomy and Ipsilateral Central Neck Dissection for T1 Low-Risk Papillary Thyroid Cancer: Single-Institution Retrospective Observational Study. *Eur J Endocrinol* (2022) 186(5):535–42. doi: 10.1530/EJE-21-0813
9. Du W, Fang Q, Zhang X, Dai L. Metastasis of cN0 Papillary Thyroid Carcinoma of the Isthmus to the Lymph Node Posterior to the Right Recurrent Laryngeal Nerve. *Front Endocrinol* (Lausanne) (2021) 10:677986. doi: 10.3389/fendo.2021.677986
10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. (2015) American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* (2016) 26(1):1–133. doi: 10.1089/thy.2015.0020
11. Amin MB, Edge SB, Greene FL. *AJCC Cancer Staging Manual. 8th ed*. New York: Springer (2017).
Term Locoregional Recurrence in Papillary Thyroid Carcinoma After Total Thyroidectomy. *Thyroid* (2013) 23(9):1087–98. doi: 10.1089/thy.2012.0608

16. Barczynski M, Konturek A, Stopa M, Nowak W. Prophylactic Central Neck Dissection for Papillary Thyroid Cancer. *Br J Surg* (2013) 100(3):410–8. doi: 10.1002/bjs.8985

17. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A Multicenter Cohort Study of Total Thyroidectomy and Routine Central Lymph Node Dissection for cN0 Papillary Thyroid Cancer. *Surgery* (2011) 150(6):1048–57. doi: 10.1016/j.surg.2011.09.003

18. Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M. Routine Central Neck Dissection in Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *Laryngoscope* (2012) 122(4):797–804. doi: 10.1002/lary.22162

19. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic Central Neck Dissection and Local Recurrence in Papillary Thyroid Cancer: A Meta-Analysis. *Ann Surg Oncol* (2010) 17(12):3287–93. doi: 10.1245/s10434-010-1137-6

20. Eun YG, Lee YC, Kwon KH. Predictive Factors of Contralateral Paratracheal Lymph Node Metastasis in Papillary Thyroid Cancer: Prospective Multicenter Study. *Otolar yngol Head Neck Surg* (2014) 150(2):210–5. doi: 10.1177/0194599813514726

21. Lee KE, Chung IY, Kang E, Koo do H, Kim KH, Kim SW, et al. Ipsilateral and Contralateral Central Lymph Node Metastasis in Papillary Thyroid Cancer: Patterns and Predictive Factors of Nodal Metastasis. *Head Neck* (2013) 35 (5):672–6. doi: 10.1002/hed.23016

22. Koo BS, Choi EC, Yoon YH, Kim DH, Kim EH, Lim YC. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. *Ann Surg* (2009) 249(5):840–4. doi: 10.1097/SLA.0b013e3181e40919

23. Roh JL, Kim JM, Park CI. Central Lymph Node Metastasis of Unilateral Papillary Thyroid Carcinoma: Patterns and Factors Predictive of Nodal Metastasis, Morbidity, and Recurrence. *Ann Surg Oncol* (2011) 18(8):2245–50. doi: 10.1245/s10434-011-1600-z

24. Hwang HS, Orloff LA. Efficacy of Preoperative Neck Ultrasound In the Detection of Cervical Lymph Node Metastasis From Thyroid Cancer. *Laryngoscope* (2011) 121(8):1798–805. doi: 10.1016/j.lary.2011.04.028

25. Wu LM, Gu HY, Qu XH, Zheng J, Zhang W, Yin Y, et al. The Accuracy of Ultrasonography in the Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients With Papillary Thyroid Carcinoma: A Meta-Analysis. *Eur J Radiol* (2012) 81(8):1798–805. doi: 10.1016/j.ejrad.2011.04.028

26. Wei T, Chen R, Zou X, Liu F, Li Z, Zhu J. Predictive Factors of Contralateral Paratracheal Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma. *Eur J Surg Oncol* (2015) 41(6):746–50. doi: 10.1016/j.ejso.2015.02.013

27. Chen Q, Wei T, Wang XL, Li ZH, Du ZH, Zhu JQ. The Total Number of Prelaryngeal and Pretracheal Lymph Node Metastases: Is it a Reliable Predictor of Contralateral Central Lymph Node Metastasis in Papillary Thyroid Carcinoma? *J Surg Res* (2017) 214:162–7. doi: 10.1016/j.jss.2015.02.056

28. Zhou L, Li H, Liang W, Gao C, Chen B. Pretracheal-Laryngeal Lymph Nodes in Frozen Section Predicting Contralateral Paratracheal Lymph Nodes Metastasis. *Eur J Surg Oncol* (2020) 46(10 Pt A):1829–34. doi: 10.1016/j.ejso.2020.06.048

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Chen, Liu, Lu, Zhang, Su, Liu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**